No 5239

Prescription limits per physician prescribing for EOPYY

Having considered:

.

We decide:

1. We determine that the monthly limit for prescribing as regards the total prescriptions of each physician, may not exceed 80% of the average monthly expenditure for the said physician during 2013.

2. The following is excluded from the application of this decision:

A. Special categories of physicians, such as physicians that prescribe medicinal products to KAPI, working physicians, NGOs physicians, public service hospitals physicians, physicians in multimedical facilities for security agencies and EOPYY physicians. HDIKA will incorporate in the electronic prescribing software all changes/amendments per category of excluded physicians.

B. Patients suffering from terminal chronic neuropathy (undergoing dialysis, peritoneal dialysis and transplant), terminal heart disease patients (mechanical heart, terminal heart failure, heart transplant), liver failure patients (terminal liver failure, non-compensated cirrhosis, liver transplant), patients undergoing transplant of liquid or solid body organs and tissues: HDIKA, via the diagnosis according to ICD-10, must apply the non-measurement of the value of the prescriptions of the above diseases to the prescription limit of physicians.

C. Medicinal products whose use is pre- approved by EOPYY via the Committees thereof, as set out in Annex 1.

D. The physicians of the island of Cephalonia, for the whole 2014.

E. Physicians of hospitals and private clinics are excluded from the application of the measure, as regards the medicinal products prescribed to hospitalised or patients exiting the hospital or clinic after hospitalization, however the fall into the scope of application of the said measure, in relation to medicinal products prescribed to outgoing patients and are granted by the private pharmacies and the pharmacies of EOPYY: HDIKA will add a field on the prescription that will relate to the hospitalisation, so that EOPYY will verify the statement of the attending physician with its own available data.

3. As regards the following categories, the monthly prescription limits are calculated based on the average of their specialty in accordance with Annex 2.

A. New-entrants in Electronic Prescribing: HDIKA will see to that the physicians entering its system for the first time from 2011 and forth, will obtain the average of their specialty.

B. Physicians who have obtained a license from the competent Medical Association to operate their first private practice from 2011 and forth: the said physicians must produce to EOPYY a certificate from the relevant medical association as well as a certificate by the competent Tax Office for the commencement of their profession.

C. Physicians who did not render any treatment/medical services in 2013: These physicians must produce to EOPYY a Solemn Declaration in which they will state the reason for which they did not render any treatment/medical services as well as supporting documents that document their declaration.

D. Physicians whose visits increased in 400 per month: HDIKA will be informed of the details of the said physicians and must see to their prompt implementation.

Annex 1

	ACTIVE SUBSTANCE 1
PHARMACY	
ALDURAZYME	A–L–IDURONIDASE
BOTOX	BOTULINUM TOXIN
BUSILVEX	BUSULFAN
CAYSTON	AZTREONAM LYSINE
CEREZYME	IMIGLUCERASE
DYSPORT	BOTULINUM TYPE A TOXIN HAEMAGLUTININ
EVOLTRA	CLOFARABINE
ELAPRASE	IDURSULFASE
FABRAZYME	AGALSIDASE
FORSTEO	TERIPARATIDE
ILARIS	CANAKINUMAB
KEPIVANCE	PALIFERMIN
LUCENTIS	RANIBIZUMAB
MACUGEN	PEGAPTANIB SODIUM
MYOZYME	ALGUCOSIDASE A
PREOTACT	PARATHYROID HORMONE
REPLAGAL	AGALSIDASE
REMODULIN	TREPROSTINIL SODIUM
SPRYCEL	DASATINIB
SYNAGIS	PALIVIZUMAB
TASIGNA	NILOTINIB
TORISEL	TEMSIROLIMUS
TRISENOX	ARSENIC TRIOXIDE
VISUDYNE	VERTEPORFIN
YONDELIS	TRABECTEDIN
ZAVESCA	MIGLUSTAT

In addition, medicinal products preliminarily approved by Committees of Assisted Reproduction which are set out in the following table, are also excluded:

TRADE NAME	ACTIVE SUBSTANCE
ALTERMON	FOLLICLE STIMULATING HORMONE,
BRAVELLE	UROFOLLITROPIN
ELONVA	CORIFOLLITROPIN ALFA
GONAL	FOLLITROPIN ALFA
LUVERIS	LUTROPIN ALPHA
MERIONAL	MENOTROPHINE
MENOPUR	MENOTROPHINE
PERGOVERIS	FOLLITROPIN ALFA/LUTROPIN ALFA
PUREGON	FOLLITROPIN BETA

From the innovative products that were priced in August 2013, applications have been filed and are being examined by the Committee for the following: Eylea, Fampyra, Incivo, Vïctrelis, Jakavi, Inlyta, Vyndaquel, Xalkori, Yervoy, Zelboraf, Zytlga. Xeplion, Xgeva.

	Specialty	Average of Specialty
1	ALLERGOLOGIST	5,185.34
2	PHYSICIAN	4,117.52
3	GASTROENTEROLOGIST	4,832.61
4	GENERAL PHYSICIAN	13,988.12
5	OBSTETRICIAN – GYNAECOLOGIST	1,575.11
6	DERMATOLOGIST – VENEREALOGIST	2,887.61
7	AUDITOR	6,699.49
S	ENDOCRINOLOGIST	5,240.46
θ	CARDIOLOGIST	5,626.26
10	NEUROLOGIST	15,509.44
11	ORTHOPAEDIST	2,023.79
12	UROLOGIST	2,809.83
13	OCULIST	1,210.00
14	PATHOLOGIST	10,206.51
15	PAEDIATRICIAN	3,155.33
16	PULMONOLOGIST – TB SPECIALIST	4,947.87
17	RHEUMATOLOGIST	26,578.68
19	SURGEON	664.31
20	PSYCHIATRIST	5,487.27
21	OTOLARYNGOLOGIST	696.83
22	VASCULAR SURGEON	871.58
23	HAEMATOLOGIST	23,661.56
24	MEDICAL IMAGING SPECIALIST	987,33
25	RADIOTHERAPIST – ONCOLOGIST	2,498.80
26	ANAESTHESIOLOGIST	1,023.32
27	FACE-JOWL SURGEON	178.03
28	EMPLOYMENT MEDICINE	504.27
29	MEDICAL CORONER	5,733.76
30	PUBLIC HEALTH MEDICINE	4,506.48
31	CYTOLOGIST	438.48
32	MICROBIOLOGIST	2,296.85
33	NEUROSURGEON	439.12
34	NEPHROLOGIST	12,902.52
35	DENTIST	36.93
36	ORTHODONTIST	9.22
37	PATHOLOGOANATOMIST	80.44
38	CHILDREN SURGEON	274.13
39	CHILDREN PSYCHIATRIST	459.95
40	PLASTIC SURGEON	135.54

Annex 2

	Specialty	Average of Specialty (continued)
41	PHYSICAL MEDICINE – REHABILITATION	1,385.54
42	THORAX SURGEON	3960.1
43	GENERAL MEDICINE CERTIFICATE	11,411.10
44	NEUROLOGIST – PSYCHIATRIST	11,534.97
45	PATHOLOGIST – ONCOLOGIST	45,450.68
46	MEDICAL BIO-PATHOLOGY	218.28
48	NUCLEAR MEDICINE PHYSICIAN	1,697.63
49	PHYSICIANS WITH NO SPECIALTY	3,227.44

This decision must be published in the Government Gazette.

Athens, February 11 2014

The President

DEMETRIOS KONTOS